Search results for "Piperazines"

showing 10 items of 135 documents

Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors

2020

Abstract Objectives This study evaluated the emergence of mutations associated with integrase strand transfer inhibitors (INSTI) resistance (INSTI-RMs) and the integrase evolution in human immunodeficiency virus type 1 (HIV-1) infected patients treated with this drug class. Methods The emergence of INSTI-RMs and integrase evolution (estimated as genetic distance between integrase sequences under INSTI treatment and before INSTI treatment) were evaluated in 107 INSTI-naive patients (19 drug-naive and 88 drug-experienced) with two plasma genotypic resistance tests: one before INSTI treatment and one under INSTI treatment. A logistic regression analysis was performed to evaluate factors associ…

Male0301 basic medicineIntegrase inhibitorHIV InfectionsHIV IntegraseQuinolonesPiperazineschemistry.chemical_compound0302 clinical medicineHIV-1 integrase resistanceImmunology and Allergy030212 general & internal medicineIntegrase inhibitorSubtype.genetic distancebiologyElvitegravirMiddle AgedQR1-502Integraseintegrase inhibitorsDolutegravirHiv 1 integraseFemaleHeterocyclic Compounds 3-Ringmedicine.drugAdultMicrobiology (medical)Settore MED/17 - Malattie InfettiveGenotypePyridones030106 microbiologyImmunologyMicrobiologysubtypeEvolution Molecular03 medical and health sciencesRaltegravir PotassiumDrug Resistance ViralOxazinesmedicineHumansIn patientHIV Integrase InhibitorsPolymorphismbusiness.industryHIV-1 integrase resistance; genetic distance; integrase inhibitors; polymorphisms; subtypeRaltegravirVirologyLogistic ModelschemistryMutationHIV-1Genotypic resistancebiology.proteinpolymorphismsbusinessJournal of Global Antimicrobial Resistance
researchProduct

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

2019

Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At…

Male0301 basic medicineOncologyPyridinesReceptor ErbB-2PhysiologyClinical BiochemistryPiperazineschemistry.chemical_compound0302 clinical medicineExemestaneAntineoplastic Combined Chemotherapy Protocolsadvanced breast cancer; hormonal therapy; endocrine resistance; palbociclib; real-world settingBreastAged 80 and overadvanced breast cancerhormonal therapyadvanced breast cancer hormonal therapy; endocrine resistance; palbociclib; real-world settingMiddle AgedTreatment OutcomeReceptors Estrogen030220 oncology & carcinogenesisToxicityFemaleReceptors Progesteronemedicine.drugAdultadvanced breast cancer hormonal therapy; endocrine resistance; palbociclib; real-world setting; Physiology; Clinical Biochemistry; Cell Biologymedicine.medical_specialtypalbociclibBreast NeoplasmsPalbociclibNeutropeniaadvanced breast cancer hormonal therapyDisease-Free Survivalendocrine resistance03 medical and health sciencesInternal medicinereal-world settingmedicineHumansAgedEverolimusSettore MED/06 - ONCOLOGIA MEDICAbusiness.industryCancerCell Biologymedicine.diseaseConfidence interval030104 developmental biologychemistryMED/06 - ONCOLOGIA MEDICAbusinessHormone
researchProduct

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

2020

Inhibidor d'AKT; Càncer avançat; Fase I Inhibidor de AKT; Cáncer avanzado; Fase I AKT inhibitor; Advanced cancer; Phase I Background This phase Ib study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the oral AKT inhibitor ipatasertib and chemotherapy or hormonal therapy in patients with advanced or metastatic solid tumors to determine combined dose-limiting toxicities (DLTs), maximum tolerated dose, and recommended phase II doses and schedules. Patients and methods The clinical study comprised four combination treatment arms: arm A (with docetaxel), arm B [with mFOLFOX6 (modified leucovorin, 5-fluorouracil, and oxaliplatin)], arm C (with paclitaxel), and …

Male0301 basic medicinemedicine.medical_specialtyMaximum Tolerated Dosemedicine.medical_treatmentCàncer - Quimioteràpia:Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores]GastroenterologyAKT inhibitorPiperazinesMedicaments antineoplàstics - Efectes secundaris:neoplasias [ENFERMEDADES]03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy Protocols:Other subheadings::Other subheadings::/adverse effects [Other subheadings]medicineadvanced cancerHumansEnzalutamide:terapéutica::protocolos clínicos::protocolos antineoplásicos::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Adverse effectChemotherapybusiness.industryHematologyphase I:Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Oxaliplatin:Neoplasms [DISEASES]Pyrimidines030104 developmental biologyOncologyDocetaxelTolerabilityPaclitaxelchemistryResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisbusinessmedicine.drugAnnals of Oncology
researchProduct

Mathematical modelling of in situ and in vitro efflux of ciprofloxacin and grepafloxacin

2005

Abstract The efflux process due to p-glycoprotein-like mechanisms of ciprofloxacin (CIP) and grepafloxacin (GRX) has been studied “in situ” in rats and “in vitro” in Caco-2 cells. The results were modelled by a curve fitting procedure which allowed the characterization of the passive (Pd) and carrier mediated parameters (Vm and Km) from the raw data without initial velocities estimation. CIP absorption in rat was characterized as a passive diffusion at the assayed concentrations. Although the involvement of an efflux transporter cannot be ruled out, its relevance in the transport of the fluoroquinolone is negligible. In GRX absorption, an efflux process is implicated and it is detected in b…

MaleAbsorption (pharmacology)In situCell Membrane PermeabilityPharmaceutical ScienceModels BiologicalPiperazinesDiffusionAnti-Infective AgentsCiprofloxacinIntestine SmallmedicineAnimalsHumansRats WistarAntibacterial agentChemistryTransporterIn vitroGrepafloxacinRatsPerfusionIntestinal AbsorptionBiochemistryPermeability (electromagnetism)BiophysicsEffluxCaco-2 CellsFluoroquinolonesmedicine.drugInternational Journal of Pharmaceutics
researchProduct

Serotonergic modulation of rat pineal gland activity: in vivo evidence for a 5-Hydroxytryptamine(2C) receptor involvement

2000

There are some suggestions that, in the pineal gland, serotonin acts not only as a precursor of melatonin but also plays a role in the modulation of the pineal biosynthetic activity. To corroborate this possible neuromodulatory role of 5-hydroxytryptamine (serotonin) (5-HT) on the pineal gland, the effects of two 5-HT(2) receptor agonists meta-chlorophenylpiperazine (m-CPP) and 1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane were assessed in vivo on pineal N-acetyltransferase (NAT) activity and melatonin content in rats. m-CPP potentiated the enhancement of NAT activity and pineal melatonin content induced by isoproterenol administration during daytime, whereas it did not affect the diurnal …

MaleArylamine N-Acetyltransferasepineal glandAmphetaminesIsoproterenolPiperazinesserotoninergic modulation5-hydroxytryptamineRatsReceptors SerotoninReceptor Serotonin 5-HT2CSettore BIO/14 - FarmacologiaAnimalsRats WistarMelatonin
researchProduct

The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey

2008

AbstractThis study related clinical effects to daily doses and serum concentrations of ziprasidone by retrospective analysis of data from a therapeutic drug monitoring (TDM) survey established for patients treated with the new antipsychotic drug. In the total sample of 463 patients ziprasidone doses ranged between 20 and 320 mg/d and correlated significantly (r2 = 0.093, P < 0.01) with serum concentrations. The latter were highly variable within and between individual patients (between patients median 67 ng/ml, 25–75th percentile 40–103 ng/ml). Pharmacokinetic interactions with comedication played a minor role. According to the clinical global impressions (CGI) scale most of the 348 pati…

MaleDrugmedicine.drug_classmedia_common.quotation_subjectAtypical antipsychotic030204 cardiovascular system & hematologyPharmacologySeverity of Illness Index030226 pharmacology & pharmacyDrug Administration SchedulePiperazines03 medical and health sciences0302 clinical medicinePharmacotherapyPharmacokineticsHumansMedicineZiprasidoneRetrospective Studiesmedia_commonDose-Response Relationship Drugmedicine.diagnostic_testMood Disordersbusiness.industryDrug interactionThiazolesPsychiatry and Mental healthTreatment OutcomePsychotic DisordersTherapeutic drug monitoringAnesthesiaPharmacodynamicsDrug Therapy CombinationFemaleDrug MonitoringbusinessAntipsychotic Agentsmedicine.drugEuropean Psychiatry
researchProduct

Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists

2011

Rationale Impulsivity is associated with a number of psychiatric disorders, most notably attention deficit/hyperactivity disorder (ADHD). Drugs that augment catecholamine function (e.g. methylphenidate and the selective noradrenaline reuptake inhibitor atomoxetine) have clinical efficacy in ADHD, but their precise mechanism of action is unclear. Objective The objective of this study is to investigate the relative contribution of dopamine (DA) and noradrenaline (NA) to the therapeutic effects of clinically effective drugs in ADHD using rats selected for high impulsivity on the five-choice serial reaction time task (5CSRTT). Methods We examined the effects of direct and indirect DA and NA rec…

MaleImpulsivityQuinpiroleDopamineSerial LearningAtomoxetine HydrochlorideImpulsivityChoice BehaviorPiperazines03 medical and health sciences0302 clinical medicineQuinpiroleDopaminemental disordersAnimals Outbred StrainsReaction TimemedicineAnimalsAttentionOriginal InvestigationPharmacologyPropylaminesMethylphenidateDopaminergicAtomoxetineGBR-12909Adrenergic AgonistsGuanfacineRats030227 psychiatry3. Good healthGuanfacineSumaniroleFive-choice serial reaction time taskAtomoxetine; Dopamine; Five-choice serial reaction time task; GBR-12909; Guanfacine; Impulsivity; Methylphenidate; Noradrenaline; Quinpirole; Sumanirole; Adrenergic Agonists; Animals; Animals Outbred Strains; Atomoxetine Hydrochloride; Attention; Benzimidazoles; Choice Behavior; Dopamine Agonists; Guanfacine; Impulsive Behavior; Male; Methylphenidate; Piperazines; Propylamines; Quinpirole; Rats; Reaction Time; Serial Learning; PharmacologyAnesthesiaDopamine AgonistsImpulsive BehaviorNoradrenalineAtomoxetineMethylphenidateBenzimidazolesmedicine.symptomPsychologyNeuroscience030217 neurology & neurosurgerymedicine.drugAtomoxetine hydrochloride
researchProduct

Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties.

2013

Introduction Aripiprazole, an atypical antipsychotic drug with mixed antagonism and agonism on dopamine D2 and serotonin receptors, is a substrate of the efflux transporter P-glycoprotein (P-gp). Here we tested the pharmacodynamic consequences of these properties in a P-gp deficient mouse model by studying the effects of aripiprazole and of ziprasidone on motor coordination. Methods The motor behaviour of wild-type (WT) and P-gp deficient [abcb1ab(-/-)] mice was investigated on a RotaRod. Mice received acute injections of either aripirazole or ziprasidone. For comparison, the dopamine receptor antagonist haloperidol and serotonin receptor ligands buspirone and ketanserin were also applied. …

MaleKetanserinmedicine.drug_classAripiprazoleAtypical antipsychoticPharmacologyMotor ActivityQuinolonesRotarod performance testPiperazinesBuspironeMiceDopamine receptor D2medicineAnimalsPharmacology (medical)ZiprasidoneATP Binding Cassette Transporter Subfamily B Member 1Mice KnockoutChemistryGeneral MedicineBuspironeSerotonin Receptor AgonistsPsychiatry and Mental healthThiazolesDopamine receptorRotarod Performance TestHaloperidolAripiprazoleKetanserinSerotonin Antagonistsmedicine.drugAntipsychotic AgentsPharmacopsychiatry
researchProduct

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, second…

2002

Abstract Imatinib mesylate, a tyrosine kinase inhibitor targeting bcr-abl, platelet-derived growth factor receptor (PDGF-R), and c-Kit, effectively induces hematologic and cytogenetic remissions in bcr-abl+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with only mild to moderate side effects. Here, we describe the successful treatment of a 64-year-old man with c-Kit+ secondary acute myeloid leukemia (AML) refractory to standard chemotherapy. Upon 2 weeks of imatinib mesylate administration, the patient achieved a complete hematologic remission in peripheral blood. In addition, complete clearance of leukemic blasts in bone marrow and a significant cytogenetic response…

MaleMyeloidmedicine.drug_classmedicine.medical_treatmentImmunologyAntineoplastic AgentsBiochemistryTyrosine-kinase inhibitorPiperazinesBone MarrowRecurrencehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineSecondary Acute Myeloid LeukemiaHumansReceptors Platelet-Derived Growth FactorEnzyme InhibitorsneoplasmsSalvage TherapyChemotherapyAnemia Refractory with Excess of Blastsbusiness.industryAnemia RefractoryDaunorubicinRemission InductionCytarabineMyeloid leukemiaCell BiologyHematologyExonsMiddle Agedmedicine.diseaseNeoplasm ProteinsLeukemiaLeukemia Myeloid AcuteProto-Oncogene Proteins c-kitmedicine.anatomical_structureImatinib mesylatePyrimidinesDrug Resistance NeoplasmImmunologyBenzamidesCancer researchDisease ProgressionImatinib MesylateNeoplastic Stem CellsBone marrowbusinessBlood
researchProduct

Nicotinic drugs and postganglionic sympathetic transmission

1970

1. Isolated rabbit hearts with the sympathetic nerves attached were perfused with Tyrode solution. The noradrenaline output into the perfusate was measured fluorimetrioally. 2. When the niootinic autoinhibition produced by infusions of nicotine, DMPP, or acetylcholine (in the presence of atropine) was fully developed, the output of noradrenaline evoked by electrical stimulation of the postganglionic sympathetic nerves was not depressed. 3. Acetylcholine in the presence of atropine produced a transitory facilitation of the noradrenaline output evoked by sympathetic nerve stimulation. 4. Prolonged infusion of DMPP caused an adrenergic neurone block which was not observed after nicotine, or ac…

MaleNicotinemedicine.medical_specialtySympathetic nervous systemSympathetic Nervous SystemReceptors DrugAdrenergicStimulationIn Vitro TechniquesSynaptic TransmissionPiperazinesNicotineNorepinephrineNorepinephrineInternal medicinemedicineAnimalsFluorometryGanglia AutonomicNerve EndingsPharmacologyChemistryHeartGeneral MedicineAcetylcholineElectric StimulationPerfusionAtropineEndocrinologyNicotinic agonistmedicine.anatomical_structureDepression ChemicalFemaleRabbitsAcetylcholinemedicine.drugNaunyn-Schmiedebergs Archiv f�r Pharmakologie
researchProduct